Initial results of a multicenter phase 2 study of venetoclax in combination with R‐CHOP (VR‐CHOP) for patients with Richter SyndromeMatthew S. Davids, Philip A. Thompson, Jennifer L. Crombie et al.|Hematological Oncology|2023Cited by 23
74 | A MULTICENTER PHASE II STUDY OF GLOFITAMAB PLUS POLATUZUMAB‐R‐CHP FOR PATIENTS WITH HIGH‐RISK DIFFUSE LARGE B‐CELL LYMPHOMAJennifer L. Crombie, Juan Pablo Alderuccio, Robert Redd et al.|Hematological Oncology|2025Cited by 3
227 | RITUXIMAB AND EPCORITAMAB AS FIRST‐LINE THERAPY FOR PATIENTS WITH HIGH‐TUMOR BURDEN FOLLICULAR LYMPHOMA: FIRST RESULTS OF A MULTICENTER PHASE II TRIALR. Merryman, Yazeed Sawalha, D. S. Wallace et al.|Hematological Oncology|2025Cited by 1
667 | REAL‐WORLD SAFETY AND EFFICACY OF EPCORITAMAB FOR PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMASAllison M. Bock, Saira Ahmed, Lei Feng et al.|Hematological Oncology|2025Cited by 0
161 | OUTCOMES OF GLOFITAMAB AND EPCORITAMAB IN R/R DLBCL ELDERLY PATIENTS: A REAL‐WORLD EVIDENCE STUDY FROM THE CUBIC CONSORTIUMAmrita Chauhan, Liangyi Chen, Sairah Ahmed et al.|Hematological Oncology|2025Cited by 0